Caribou Biosciences (CRBU) Stock Price, News & Analysis

Company Overview

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA. Its therapies are intended to enhance the persistence, activity and availability of engineered immune cells by making targeted genetic changes during cell development. These candidates remain investigational and have not been approved for general commercial use.

Founded in 2011 and headquartered in Berkeley, California, Caribou was built around CRISPR technology co-developed by a group that included Nobel Prize-winning scientist Jennifer Doudna. Rachel Haurwitz, Ph.D., a co-founder of the company, has served as its president and chief executive officer. Caribou conducts its biotechnology development primarily in the United States and works with research, clinical and industry partners to advance its cell-therapy programs.

Key Stats

• Today's Range: $1.13 to $1.22
• 50-Day Range: $1.19 to $1.76
• 52-Week Range: $1.13 to $3.54
• Volume: 2.52 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $121.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Moderate Buy

Caribou Biosciences Stock Analysis - MarketRank™

Caribou Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 508th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Caribou Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Caribou Biosciences has a consensus price target of $7.75, representing about 582.8% upside from its current price of $1.14.

Amount of Analyst Coverage

Caribou Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($0.88) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Caribou Biosciences is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Caribou Biosciences is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Caribou Biosciences has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.24% of the float of Caribou Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Caribou Biosciences has a short interest ratio ("days to cover") of 9.49.

Change versus previous month

Short interest in Caribou Biosciences has recently increased by 3.82%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Caribou Biosciences does not currently pay a dividend.

Dividend Growth

Caribou Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.59

News Sentiment

Caribou Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Caribou Biosciences this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for CRBU on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.54% of the stock of Caribou Biosciences is held by insiders.

Percentage Held by Institutions

77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRBU
• CIK: 1619856
• Web: cariboubio.com
• Phone: 510-982-6030
• Fax: N/A
• Employees: 97
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Caribou Biosciences: $7.75
• High Price Target: $11.00
• Low Price Target: $5.00
• Potential Upside/Downside: +582.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$148.12 million
• Net Margins: -1,030.42%
• Pretax Margin: -1,035.90%
• Return on Equity: -89.11%
• Return on Assets: -62.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.49
• Quick Ratio: 6.49

Sales & Book Value

• Annual Sales: $11.16 million
• Price / Sales: 10.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 107,210,000
• Free Float: 98,052,000
• Market Cap: $121.68 million
• Optionable: Optionable
• Beta: 2.31